切换至 "中华医学电子期刊资源库"
高级检索
中华老年骨科与康复电子杂志

中华老年骨科与康复电子杂志 ›› 2019, Vol. 05 ›› Issue (04) : 206 -210. doi: 10.3877/cma.j.issn.2096-0263.2019.04.005

所属专题： 文献；

骨质疏松

唑来磷酸钠联合骨化三醇治疗原发性骨质疏松症的疗效观察
刘宇航1, 张永明1, 王建华1,†()   
  1. 1. 300457　天津市泰达医院骨二科
  • 收稿日期:2019-01-28 出版日期:2019-08-05
  • 通信作者: 王建华
  • 基金资助:
    国家自然科学基金(30772193)

Observation of curative effect of zolai sodium phosphate combined with trialcohol in treatment of primary osteoporosis

Yuhang Liu1, Yongming Zhang1, Jianhua Wang1,†()   

  1. 1. Department of Orthopedic, Tianjin TEDA Hospital, Tianjin 300457, China
  • Received:2019-01-28 Published:2019-08-05
  • Corresponding author: Jianhua Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘宇航, 张永明, 王建华. 唑来磷酸钠联合骨化三醇治疗原发性骨质疏松症的疗效观察[J]. 中华老年骨科与康复电子杂志, 2019, 05(04): 206-210.

Yuhang Liu, Yongming Zhang, Jianhua Wang. Observation of curative effect of zolai sodium phosphate combined with trialcohol in treatment of primary osteoporosis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2019, 05(04): 206-210.

目的

探讨唑来磷酸钠联合骨化三醇治疗骨质疏松症的临床效果。

方法

前瞻性收集2012年10月至2017年10月天津市泰达医院收治的203例骨质疏松症患者，采用随机数字表法将其分为唑来磷酸钠组（A组）和唑来磷酸钠联合骨化三醇（B组），A组102例，B组101例，比较两组患者治疗前后的骨密度变化、骨代谢情况、不良反应等情况。

结果

203例患者均获得完整随访，随访率100%，随访时间3~5年，平均（3.9±0.5）年。治疗前两组患者的髋部骨密度[A组（0.557±0.052）g/cm3，B组（0.554±0.056）g/cm3]、腰椎骨密度[A组（0.669±0.047）g/cm3，B组（0.670±0.047）g/cm3]无明显差异，治疗后腰椎骨密度水平[A组（0.863±0.023）g/cm3，B组（0.870±0.021）g/cm3]均有显著改善，与治疗前相比，差异均有统计学意义（t=38.661，t=38.152，P<0.05），髋部骨密度水平均有改善[A组（0.720±0.023）g/cm3，B组（0.750±0.044）g/cm3]，与治疗前相比，差异均有统计学意义（t=28.653，t=32.533，P<0.05），治疗后组间差异有统计学意义（t=2.001，t=5.921，P<0.05）；两组患者治疗前血钙指标[A组（2.200±0.059）mmol/L，B组（2.201±0.054）mmol/L]无明显差异，治疗后[A组（2.211±0.060）mmol/L，B组（2.323±0.044）mmol/L]B组血钙变化明显，与A组比较差异有统计学意义（P<0.05）。B组（15.8%）的不良反应发生率低于A组（33.3%），两组患者均无严重药物不良反应发生。

结论

唑来磷酸钠联合骨化三醇可提高骨质疏松患者骨密度，改善骨代谢状态，并且降低药物不良反应的发生率。

关键词: 骨质疏松症, 唑来磷酸钠, 骨化三醇
Objective

To investigate the clinical effect of sodium zoledronate combined with calcitriol in the treatment of osteoporosis.

Methods

A prospective study of 203 patients with osteoporosis admitted to Tianjin TEDA Hospital from October 2012 to October 2017 was divided into three groups: the sodium zoledronate group (group A) and the combination of sodium zoledronate. Calcitriol (group B), 102 patients in group A and 101 patients in group B. The changes of bone mineral density, bone metabolism and adverse reactions were observed before and after treatment. All the 203 patients had been followed, The rate was 100% and lasted 3-5 years (3.891±0.501 on average). There was no significant difference in bone mineral density of the hip [group A (0.557±0.052) g/cm3, group B (0.554±0.056) g/cm3] and the lumbar vertebrae [group A (0.669±0.047) g/cm3, group B (0.670±0.047) g/cm3] between the two groups before treatment. The bone mineral density of the lumbar vertebrae improved after treatment [group A (0.863±0.023) g/cm3, group B (0.870±0.021) g/cm3], compared with before treatment, the difference was statistically significant (t=38.661, t=38.152, P<0.05). The hip bone mineral density level was improved [group A (0.720±0.023) g/cm3, group B (0.750±0.044) g/cm3], compared with before treatment, the difference was statistically significant (t=28.653, t=32.533, P<0.05). There was significant difference between the two groups after treatment (t=2.001, t=5.921, P<0.05), there was no significant difference in blood calcium index between the two groups before treatment [group A (2.200±0.059) mmol/L, group B (2.201±0.054) mmol/L]. The blood calcium in group B was significantly changed after treatment [group A (2.211±0.060) mmol/L, group B (2.323±0.044) mmol/L], and the difference was statistically significant (P<0.05). The incidence of adverse reactions in group B (15.8%) was lower than that in group A (33.3%), and no serious adverse drug reactions occurred in either group.

Conclusion

Sodium zoledronate combined with calcitriol can increase bone mineral density, improve bone metabolism and reduce the incidence of adverse drug reaction-s in patients with osteoporosis.

Key words: Osteoporosis, Zoledronic Acid, Calcitriol
表1 两组骨质疏松患者治疗前一般资料比较
组别 例数 性别[例（%）] 年龄（岁，±s） 病程（年，±s）
男性 女性
A组 102 25（24.5%） 77（75.5%） 67±7 3.9±0.5
B组 101 26（25.7%） 75（74.3%） 67±6 3.9±0.5
统计值   χ2=0.157 t=0.068 t=0.403
P值   0.500 0.946 0.688
表2 两组骨质疏松患者治疗前后腰椎骨密度对比（g/cm3，±s）
组别 治疗前 治疗后 t值 P值
A组 0.669±0.047 0.863±0.023 38.661 <0.05
B组 0.670±0.047 0.870±0.021 38.152 <0.05
t值 0.193 2.001    
P值 0.847 0.047    
表3 两组骨质疏松患者治疗前后髋部骨密度对比（g/cm3，±s）
组别 治疗前 治疗后 t值 P值
A组 0.557±0.052 0.720±0.023 t=28.653 0.000
B组 0.554±0.056 0.750±0.044 t=32.533 0.000
t值 0.504 5.921    
P值 0.615 <0.01    
表4 两组骨质疏松患者治疗前后血钙浓度对比（mmol/L，±s）
组别 治疗前 治疗后 t值 P值
A组 2.200±0.059 2.211±0.060 1.639 >0.05
B组 2.201±0.054 2.323±0.044 15.279 <0.05
t值 1.380 17.608    
P值 0.169 <0.01    
1
Abe Y, Iba K, Sasaki K, et al. Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice [J]. J Bone Miner Metab, 2015, 33(2): 125-134.
2
Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials [J]. Int J Clin Pract, 2012, 66(2): 199-209.
3
Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is≥33 ng/ml [J]. Osteoporos Int, 2012, 23(10): 2479-2487.
4
Peris P, Martínez-Ferrer A, Monegal A, et al. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis [J]. Bone, 2012, 51(1): 54-58.
5
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group [J]. Osteoporos Int, 1994, 4(6): 368-381.
6
冯燕茹,黄庆森.老年性骨质疏松症诊断的进展[J].中国骨伤,2001, 14(11): 42-44.
7
Xia WB, He SL, Xu L, et al. Rapidly increasing rates of hip fracture in Beijing, China [J]. J Bone Miner Res, 2012, 27(1): 125-129.
8
Dai K, Zhang Q, Fan T, et al. Estimation of resource utilization associated with osteoPorotichiP fracture and level ofPost-acute care in China [J]. Curr Med Res Opin, 2007, 23(12): 2937-2943.
9
中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南[J].中华骨质疏松和骨矿盐疾病杂志, 1994, 10(5): 51-52.
10
陆琳松,孙俊刚,钟惠琴,等.唑来膦酸对新疆哈萨克族老年男性骨质疏松患者的疗效观察[J].中国药物与临床, 2015, 15(11): 1553-1556.
11
张青,赵蓓初,李建力.唑来磷酸钠的药理作用及临床应用[J].实用临床医药杂志, 2006, 10(4): 132-134.
12
Pan B, To LB, Farrugia AN, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cels in vitro [J]. Bone, 2004, 34(1): 112-123.
13
程义勇.《中国居民膳食营养素参考摄入量》2013修订版简介[J].营养学报, 2014, 36(4): 313-317.
14
冯和林,王进,许建发,等.椎体后凸成形术联合唑来磷酸钠治疗骨质疏松性椎体压缩骨折的临床疗效[J].河北医药, 2016, 38(13): 1953-1956.
15
翟翠云,王洪光.骨化三醇的临床应用与不良反应[J].中国医药技术经济与管理, 2008, 2(9): 69-72.
16
中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017) [J].中国全科医学, 2017, 20(32): 3963-3982.
17
付强,刘源.钙、磷与维生素D对动物骨代谢的影响研究进展[J].中国比较医学杂志, 2006, 16(8): 502-505.
18
Gardiner EM, BaldockPA, Thomas GP, et al. Increased formation and decreased resorPtion of bone in mice with elevated vitamin DrecePtor in mature cells of the osteoblastic lineage [J]. FASEB J, 2000, 14(13): 1908-1916.
19
Kveiborg M, Rattan SI, Clark BF, et al. Treatment with 1,25-dihydroxyvitamin D3 reduces impairment of human osteoblast functions during cellular aging in culture [J]. J Cell Physiol, 2001, 186(2): 298-306.
20
宁志伟.维生素D与骨质疏松症[J].中国医学前沿杂志:电子版, 2015, 7(10): 8-14.
21
Catalano A, Morabito N, Atteritano M, et al. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis [J]. Calcif Tissue Int, 2012, 90(4): 279-285.
[1] 杨霁, 黄顺梅, 王安鸽, 吴月, 杨云梅. 杭州地区老年人群中肌少症患病情况及其与骨质疏松症的相关性分析[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 207-210.
[2] 杜牧, 陈晓波, 宋福英, 刘子勤, 钱坤. CYP27B1基因突变所致维生素D依赖性佝偻病ⅠA型患儿临床特征与基因分析[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(02): 175-184.
[3] 陆宜仙, 张震涛, 夏德萌, 王家林. 巨噬细胞极化在骨质疏松中调控作用及机制的研究进展[J]. 中华损伤与修复杂志(电子版), 2023, 18(06): 538-541.
[4] 陈跃圻, 罗睿, 向涵, 余泳妍, 余挺. 骨质疏松症与牙周炎的因果关系：一项两样本孟德尔随机化研究[J]. 中华口腔医学研究杂志(电子版), 2023, 17(04): 292-298.
[5] 王明, 陈萍. 地舒单抗导致颌骨骨坏死一例及文献复习[J]. 中华口腔医学研究杂志(电子版), 2022, 16(03): 180-183.
[6] 张茜, 刘叶青, 康雪莹, 孙兵兵, 刘岩, 胡丽叶, 周亚茹. 血清铁蛋白与绝经后骨质疏松症的相关性分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(03): 166-171.
[7] 许航, 崔宇韬, 任广凯, 刘贺, 王雁冰, 彭传刚, 吴丹凯. 骨质疏松症关键基因的筛选及生物信息学分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(01): 18-22.
[8] 覃成禹, 周昊楠, 陈远明. 葛根素对绝经后骨质疏松大鼠不同部位骨骼的抗骨质疏松作用差异的研究[J]. 中华老年骨科与康复电子杂志, 2023, 09(01): 23-27.
[9] 雷礼辉, 李峰, 罗光平, 刘洪, 杨骐彰, 吴涛, 翁睿. 椎体CT值对原发性骨质疏松症唑来膦酸钠疗效的评价价值[J]. 中华老年骨科与康复电子杂志, 2022, 08(05): 285-289.
[10] 金万通, 薛海鹏, 周大鹏, 刘兵, 纪振钢, 马翔宇, 杨超, 张昊, 韩宁, 宗宇宁, 张咏晧, 马泽方. 3D打印结合PMMA骨水泥髓内支撑技术在老年肱骨近端骨质疏松性骨折中的应用[J]. 中华老年骨科与康复电子杂志, 2022, 08(05): 276-284.
[11] 蔡金辉, 叶浩翊, 申忱, 林良业, 刁凡登, 郭栋华, 刘志锋, 刘庆余. 椎体压缩骨折机会性筛查：常规胸部、腹部CT测量T12、L1椎体CT值的价值[J]. 中华老年骨科与康复电子杂志, 2022, 08(04): 217-223.
[12] 蔡林秀, 解强, 张曦, 高俊, 孔泳. 抗骨质疏松药物不同给药途径研究进展[J]. 中华老年骨科与康复电子杂志, 2022, 08(01): 60-64.
[13] 蔡莉萍, 燕琪慧, 郭蔚莹. TNF-α在绝经后骨质疏松症中的研究进展[J]. 中华临床医师杂志(电子版), 2022, 16(03): 274-279.
[14] 白晓辉, 张龙, 王永峰, 冯毅, 赵斌, 吕智, 徐朝健. 单侧与双侧经皮椎体成形术治疗Kummell病的疗效比较[J]. 中华老年病研究电子杂志, 2023, 10(02): 14-18.
[15] 廖才智. 丹红注射液在老年骨质疏松性髋部骨折患者术后治疗中的应用[J]. 中华老年病研究电子杂志, 2022, 09(01): 38-41.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号